Senores Pharmaceuticals Stock Screener | Share Price & Fundamental Analysis
SENORES
Pharmaceuticals
Screen Senores Pharmaceuticals share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹864.70
▲
19.75 (2.34%)
Share Price BSE
₹863.45
▲
18.30 (2.17%)
Market Cap
₹3,982.25 Cr.
P/E Ratio (TTM)
45.41
P/B Ratio
4.78
EPS (TTM)
₹16.12
Dividend Yield
-
Debt to Equity
0.58
52W High
₹865.30
52W Low
₹444.30
Operating Margin
10.00%
Profit Margin
15.38%
Revenue (TTM)
₹117.00
EBITDA
₹22.00
Net Income
₹18.00
Total Assets
₹1,227.00
Total Equity
₹812.00
Senores Pharmaceuticals Share Price History - Stock Screener Chart
Screen SENORES historical share price movements with interactive charts. Analyze price trends and patterns.
Senores Pharmaceuticals Company Profile - Fundamental Screener
Screen Senores Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SENORES shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE0RB801010
Senores Pharmaceuticals Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen SENORES balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Assets | ||||
| Total Assets | 1,227 | 622 | 131 | 59 |
| Current Assets | 722 | 251 | 51 | 27 |
| Fixed Assets | 301 | 235 | 27 | 7 |
| Liabilities | ||||
| Total Liabilities | 1,227 | 622 | 131 | 59 |
| Current Liabilities | 174 | 143 | 34 | 13 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||
| Total Equity | 812 | 232 | 46 | 37 |
| Share Capital | 46 | 31 | 10 | 9 |
| Reserves & Surplus | 740 | 174 | 36 | 28 |
Screen SENORES income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Dec |
|---|---|---|---|---|---|---|---|---|
| Revenue | 117 | 134 | 159 | 104 | 80 | 100 | 108 | 80 |
| Expenses | 95 | 104 | 112 | 80 | 59 | 77 | 77 | 64 |
| EBITDA | 22 | 30 | 47 | 24 | 21 | 23 | 31 | 16 |
| Operating Profit % | 10.00% | 20.00% | 27.00% | 22.00% | 26.00% | 21.00% | 25.00% | 19.00% |
| Depreciation | 5 | 6 | 8 | 4 | 4 | 4 | 4 | 3 |
| Interest | 5 | 5 | 6 | 3 | 5 | 5 | 6 | 3 |
| Profit Before Tax | 21 | 27 | 41 | 18 | 14 | 16 | 21 | 10 |
| Tax | 3 | 5 | 11 | 3 | 3 | 3 | 4 | 3 |
| Net Profit | 18 | 21 | 30 | 14 | 11 | 13 | 16 | 7 |
| EPS | 3.81 | 4.60 | 6.54 | 8.03 | 3.39 | 3.92 | 5.04 | 4.01 |
Senores Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen SENORES cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March |
|---|---|---|---|---|
| Operating Activities | -46 | -26 | -1 | -10 |
| Investing Activities | -430 | -54 | -48 | -24 |
| Financing Activities | 573 | 87 | 46 | 37 |
| Net Cash Flow | 98 | 8 | -3 | 2 |
Screen SENORES shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jul |
|---|---|---|---|---|---|---|
| Promoter Holding | 45.80% | 45.78% | 45.77% | 45.76% | 45.76% | 66.66% |
| FII Holding | 4.28% | 3.67% | 4.17% | 4.25% | 5.51% | 0.00% |
| DII Holding | 8.61% | 9.51% | 9.65% | 11.78% | 18.61% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 31.09% | 31.44% | 31.43% | 28.71% | 27.88% | 0.00% |
| Other Holding | 10.22% | 9.60% | 8.97% | 9.49% | 2.23% | 33.34% |
| Shareholder Count | 34,917 | 36,389 | 37,653 | 43,707 | 43,707 | 177 |
Senores Pharmaceuticals Dividend Screener - Share Yield Analysis
Screen SENORES dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Senores Pharmaceuticals Index Membership - Market Screener Classification
Screen SENORES by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Senores Pharmaceuticals Market Events Screener - Corporate Actions
Screen SENORES market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -3.98% | ||
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | -2.12% |
| 2025-07-23 | 2025-07-23 | Quarterly Result Announcement | NA | -0.19% |
| 2025-05-15 | 2025-05-15 | Quarterly Result Announcement | NA | 11.84% |
| 2025-01-23 | 2025-01-23 | Quarterly Result Announcement | NA | -6.09% |
Senores Pharmaceuticals Competitors Screener - Peer Comparison
Screen SENORES competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 427,705 | 40.28 | 54,729 | 9.71% | 10,980 | 58.99 |
| Divis Laboratories | 176,338 | 70.98 | 9,712 | 18.67% | 2,191 | 63.15 |
| Torrent Pharmaceuticals | 138,499 | 62.26 | 11,539 | 6.99% | 1,911 | 80.95 |
| Cipla | 118,573 | 22.75 | 28,410 | 7.12% | 5,291 | 38.52 |
| Dr Reddys Laboratories | 103,728 | 18.27 | 33,741 | 16.73% | 5,725 | 40.17 |
| Lupin | 101,149 | 22.61 | 22,910 | 13.74% | 3,306 | 71.67 |
| Mankind Pharma | 95,432 | 52.17 | 12,744 | 20.90% | 2,007 | 64.16 |
| Zydus Life Science | 93,333 | 18.63 | 23,511 | 18.55% | 4,615 | 52.14 |
| Aurobindo Pharma | 71,752 | 20.91 | 32,346 | 9.43% | 3,484 | 61.25 |
| Alkem Laboratories | 69,425 | 28.04 | 13,458 | 3.70% | 2,216 | 63.97 |
Senores Pharmaceuticals Company Announcements - News Screener
Screen SENORES latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-09 | Board Meeting Outcome for Outcome Of Board Meeting Held On January 07 2026 | View |
| 2026-01-05 | Board Meeting Intimation for Considering And Evaluating Proposals For Raising Funds By Way Of Issue Of Convertible Warrants On Preferential Basis To The Promotors/Promoter Group Including Determination Of Issue Price | View |
| 2026-01-03 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | View |
| 2026-01-01 | Revised Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-12-31 | Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-12-22 | Transcript Of Business Update Call | View |
| 2025-12-20 | Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-12-18 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | View |
| 2025-12-16 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-12-15 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-15 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-12-15 | Announcement under Regulation 30 (LODR)-Acquisition | View |
| 2025-12-11 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-05 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-05 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-05 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | View |
| 2025-12-05 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-06 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |